D2DR Antibodies

Santa Cruz Biotechnology features a diverse variety of D2DR monoclonal antibodies for targeting the dopamine D2 receptor (D2DR). D2DR monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). The dopamine D2 receptor plays a critical role in the central nervous system, influencing numerous physiological processes such as mood regulation, reward pathways, and motor control. Dysregulation of D2DR signaling has been implicated in several neuropsychiatric disorders, including schizophrenia and Parkinson's disease, making it a significant target for therapeutic intervention. Understanding the function and modulation of D2DR is essential for advancing research in neurobiology and pharmacology. Researchers worldwide rely on D2DR monoclonal antibodies to investigate receptor expression patterns and signaling mechanisms. Advanced detection methods using horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC) conjugates enable precise visualization of D2DR in various experimental settings. Santa Cruz Biotechnology monoclonal antibodies for D2DR support cutting-edge neuroscience research, helping scientists uncover new insights into neurological disorders and potential therapeutic approaches.